An analyst covering a mid-cap pharmaceutical company sits down with the latest quarterly filing and encounters a familiar problem. The company reports $1.2 billion in net product revenue for its lead asset. The filing also discloses gross-to-net adjustments of $800 million, implying a gross revenue of $2 billion. The drug’s WAC is listed in pricing compendia at a figure that, multiplied by estimated unit volumes, would suggest gross revenue of $2.4 billion — $400 million more than the filing reports and $1.2 billion more than the net revenue line. Three different approaches to estimating “what the drug costs” produce three different numbers. The analyst must decide which one matters.
The answer, of course, is that they all matter and none is sufficient. WAC tells you the manufacturer’s published list price, which sets the anchor for contracting and influences patient cost-sharing. Gross revenue tells you what the manufacturer invoiced before returning money through the rebate and discount architecture. Net revenue tells you what the manufacturer kept — the cash that funds R&D, operations, dividends, and share repurchases. Each metric measures a different stage of the same economic transaction, and the relationships between them are neither transparent nor stable.
The gross-to-net percentage — the proportion of gross revenue returned to the supply chain as rebates, discounts, chargebacks, and fees — is the variable that matters most for fundamental analysis and the one that is disclosed least precisely. Companies report aggregate adjustments but rarely disaggregate by program (Medicaid vs. commercial vs. 340B), by channel (retail vs. specialty), or by product in multi-asset portfolios. The analyst modeling a single drug’s net price must estimate the gross-to-net percentage from aggregate disclosure, peer comparison, and management commentary that is carefully worded to inform without revealing.
ASP data, published quarterly by CMS, provides the closest thing to an observable net price for physician-administered drugs. Because ASP reflects volume-weighted average sales prices net of most concessions, it offers a benchmark against which investor estimates can be calibrated — at least for drugs reimbursed under Medicare Part B. But ASP data arrives with a two-quarter lag, covers only one payment segment, and includes concessions like Medicaid rebates that pull the average below the commercial net price. An investor using ASP as a proxy for commercial net pricing will underestimate the drug’s commercial revenue per unit.
SSR Health provides modeled estimates of net prices that incorporate manufacturer financial data, utilization estimates, and rebate assumptions. The estimates are widely used by buyside and sellside analysts, but as the AEI has documented, the methodology’s accuracy varies by drug characteristics and distribution channel. For retail drugs with publicly traded manufacturers and transparent financial reporting, SSR estimates are generally considered reliable. For specialty drugs, small-company products, and drugs distributed through limited networks, the estimates carry uncertainty that is difficult to quantify from outside the model.
The investor’s challenge is compounded by the dynamic nature of gross-to-net economics. A drug’s GTN percentage is not fixed — it evolves over the product lifecycle as Medicaid utilization shifts, commercial rebates are renegotiated, 340B penetration changes, and competitive dynamics alter formulary positioning. A drug in its launch year may carry a GTN spread of twenty-five percent. Five years later, the same drug may face a GTN spread of fifty percent as rebate obligations accumulate and competitive pressure intensifies. Modeling net revenue over a drug’s lifecycle requires forecasting not just unit volumes and WAC trajectories but the composition and evolution of the GTN waterfall — a multi-variable estimation challenge that introduces substantial uncertainty into long-term valuation models.
The Inflation Reduction Act adds a new dimension. For drugs approaching MFP eligibility, investors must model the impact of a government-negotiated price ceiling on future cash flows. The MFP, set as a percentage of non-federal AMP, creates a hard cap on Medicare revenue per unit that may be significantly below the drug’s current net price. The timing of selection — which year CMS designates the drug for negotiation — determines when the cap applies. The percentage ceiling — 75%, 65%, or 40% of AMP depending on time on market and drug type — determines how binding the cap is. Both variables are partially predictable and partially uncertain, adding a regulatory risk factor to valuation models that did not exist before 2022.
For investors in biosimilar manufacturers, the pricing landscape is different but equally complex. Biosimilar pricing strategies must balance the need for market access — which requires discounts sufficient to incentivize payer switching from the reference biologic — against the margin compression that aggressive pricing creates. ASP-based reimbursement for biosimilars includes a temporary premium (reference ASP plus eight percent vs. ASP plus six percent for the reference product) that is intended to incentivize adoption. Whether this differential is sufficient to offset the contractual advantages that reference biologic manufacturers maintain — preferred formulary positioning, established rebate relationships, provider switching inertia — is an empirical question that varies by therapeutic category and market structure.
The fundamental problem for pharmaceutical investors is not a lack of data. It is the fragmentation of data across metrics that each answer a different question. WAC answers: what is the published price? Gross revenue answers: what was invoiced? Net revenue answers: what was kept? ASP answers: what did Medicare Part B pay, on average, two quarters ago? NADAC answers: what did retail pharmacies pay for the drug on their invoices? Each answer is accurate within its scope. None answers the question the investor actually needs answered: what will this drug’s net revenue be, per unit, across channels, next quarter and beyond?
The analyst closes the filing and opens the model. The gross-to-net assumption cell blinks, waiting for a number that is part estimate, part inference, and part informed speculation. This is pharmaceutical valuation. Every number in the model is correct. None of them is complete.
